Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Entera Bio Ltd logo
ENTX

Entera Bio Ltd

MaveScore 19 Low model confidence
Last Price US$1.66 As of Jul 10, 2026
Market Cap US$77.4m Company size context
7D Performance -0.30% Past 7 days
1Y Performance -10.05% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

102 days old

Market price date

Jul 10, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 19 Low confidence

Stored data quality

Freshness and coverage checks

16/16 Current stored snapshot

Quality

3/35 Weak

Blends latest model rank with profitability and dilution ranks.

Financial Strength

6/25 Weak

Rewards durable profitability, margins, and positive free cash flow.

Valuation Support

0/15 Weak

Favors positive earnings, positive cash flow, and lower multiples.

Momentum

10/15 Mixed

Highlights research candidates with supportive 3-month and 6-month price regimes.

Shareholder Alignment

0/10 Weak

Rewards less dilutive share behavior and enough size for liquid research coverage.

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Blends latest model rank with profitability and dilution ranks.
  • Rewards durable profitability, margins, and positive free cash flow.
  • Favors positive earnings, positive cash flow, and lower multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Prediction Screener Map

Entera Bio Ltd Overview

Industry: Biotechnology

Sector: Healthcare

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hy Read More

Entera Bio Ltd is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Entera Bio Ltd

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 08, 2026

Quarterly result summary

EPS was $47 (reported).

EPS $47 reported
Net loss -$3.5M reported
Cash $11.9M reported

What changed

  • EPS reported to $47.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Recent News



Earnings Per Share

Score 0.00/5
Entera Bio Ltd earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Return on Equity

Score 0.72/5
Entera Bio Ltd exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Entera Bio L... ENTX US$77.4m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Net Margin

Score 0.35/5
Entera Bio Ltd olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Entera Bio L... ENTX US$77.4m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Share Buyback

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Leverage

Score 3.64/5
Entera Bio Ltd attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Entera Bio L... ENTX US$77.4m
Zoetis Inc ZTS US$31.4b
IQVIA Holdin... IQV US$34.6b
Agilent Tech... A US$36.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

SEC financial statements are temporarily unavailable.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Entera Bio Ltd logo

Entera Bio Ltd

US$1.66

US$77.4m

-0.30%

-10.05%